2076975 2077203
최종편집 2024-07-17 19:27 (수)
JemperliㆍXpovio secure the reimbursements in Korea, criteria applied
상태바
JemperliㆍXpovio secure the reimbursements in Korea, criteria applied
  • Hyeokgi Lee, Newsmp
  • 승인 2023.06.18 13:16
  • 댓글 0
이 기사를 공유합니다

[Newsmp] The endometrial cancer treatment drug, Jemperli, and the multiple myeloma treatment drug, Xpovio, have passed the cancer disease deliberation committee and established reimbursement criteria.

On Wednesday, the Health Insurance Review and Assessment Service (HIRA) disclosed the results of its fourth Cancer Diseases Deliberation Committee.

GSK's Jemperli has been acknowledged for its efficacy in adult patients with recurrent or progressive endometrial cancer characterized by deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H), who are either undergoing platinum-based systemic chemotherapy or have shown disease progression after treatment.

Antengene's Xpovio has established reimbursement criteria for its effectiveness in combination therapy with dexamethasone for adult patients with relapsed or refractory multiple myeloma, but its therapeutic efficacy has not been recognized for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more systemic treatments.

The reimbursement criteria for Astellas Pharma Korea's 'Xtandi Soft' have been broadened due to the acknowledged combined effectiveness with androgen deprivation therapy (ADT) in treating metastatic hormone-sensitive prostate cancer (mHSPC), and similarly, Janssen Korea's Zytiga has also been recognized for its combined efficacy with ADT and prednisolone in the treatment of high-risk metastatic hormone-sensitive prostate cancer (mHSPC).

On the other hand, Gavreto from Roche Korea has not received recognition for its therapeutic effects in the treatment of adult patients with locally advanced or metastatic RET gene-mutated thyroid cancer requiring systemic therapy, as well as in the treatment of adult patients with locally advanced or RET fusion-positive advanced NSCLC.

Vyxeos Liposomal has failed to receive recognition for its therapeutic efficacy in the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) in adults, as well as in the treatment of newly diagnosed acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in adults.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.